Efficacy of teriparatide in patients with resolved secondary hyperparathyroidism due to vitamin D deficiency.

Simple item page
dc.contributor.authorTraina, Andrea N ++
dc.contributor.authorKane, Michael P
dc.contributor.authorBakst, Gary
dc.contributor.authorBusch, Robert S
dc.contributor.authorAbelseth, Jill M
dc.contributor.authorHamilton, Robert A
dc.date.accessioned2023-11-21T20:17:14Z
dc.date.available2023-11-21T20:17:14Z
dc.date.issued2011-01
dc.descriptionClick on the Resource Link to access the article (may not be free).
dc.description.abstractObjective: To determine the efficacy of at least 1 year of teriparatide therapy on bone mineral density (BMD), T-scores, and rates of occurrence of fractures in patients with a history of resolved secondary hyperparathyroidism due to vitamin D deficiency and to compare its efficacy with that in patients without a history of resolved secondary hyperparathyroidism. Methods: In this retrospective study based on a search of electronic medical records, we collected the following data: patient demographics, doses of calcium and vitamin D supplementation, duration of teriparatide treatment, history and treatment of secondary hyperparathyroidism, BMD information, T-scores, and any history of fractures. Paired and unpaired t tests, the Fisher exact test, and the Wilcoxon rank sum test were used for statistical analysis. Results: Ninety-five patients (7 with a history of resolved secondary hyperparathyroidism due to vitamin D deficiency and 88 without such a history) fulfilled the study inclusion criteria. Baseline characteristics (demographics, median calcium and vitamin D supplementation doses, mean BMD, mean T-scores, and fracture rates before teriparatide therapy) were similar between the 2 groups. In comparison with baseline data, after a mean of 21 months of teriparatide therapy: (1) hip BMD and T-scores did not change in either study group (with no significant differences between the 2 groups), (2) spine BMD and T-scores significantly improved in both study groups (with no significant differences between them), and (3) wrist T-scores significantly worsened in both study groups (with wrist BMD significantly lower in patients without a history of secondary hyperparathyroidism). No patients with a history of secondary hyperparathyroidism sustained a fracture while receiving teriparatide therapy versus 6 of 88 patients without a history of secondary hyperparathyroidism (P = .624). Conclusion: Patients with a history of resolved secondary hyperparathyroidism attributable to vitamin D deficiency responded to teriparatide therapy in a fashion similar to patients without such a history.
dc.description.urihttps://doi.org/10.4158/ep10228.or
dc.identifier.citationTraina AN, Kane MP, Bakst G, Busch RS, Abelseth JM, Hamilton RA. Efficacy of teriparatide in patients with resolved secondary hyperparathyroidism due to vitamin D deficiency. Endocr Pract. 2011 Jul-Aug;17(4):568-73. doi: 10.4158/EP10228.OR. PMID: 21454243.
dc.identifier.issn1530-891X
dc.identifier.other21454243
dc.identifier.urihttps://hdl.handle.net/20.500.14303/374
dc.language.isoen
dc.publisherThe College and the Association
dc.relation.ispartofEndocrine Practice
dc.rightsThis Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s). http://rightsstatements.org/vocab/InC/1.0/
dc.subjectBone Density Conservation Agents / therapeutic use
dc.subjectHyperparathyroidism, Secondary / drug therapy
dc.subjectHyperparathyroidism, Secondary / etiology
dc.subjectTeriparatide / therapeutic use
dc.titleEfficacy of teriparatide in patients with resolved secondary hyperparathyroidism due to vitamin D deficiency.
dc.typeArticle
local.departmentprogramDepartment of Pharmacy Practice
Files
Collections
Kane, Michael Publications
Pharmacy Resident Publications